Iloperidone + Placebo
Phase 2Terminated 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Post Traumatic Stress Disorder
Conditions
Post Traumatic Stress Disorder
Trial Timeline
Jul 1, 2013 → Feb 1, 2014
NCT ID
NCT01917318About Iloperidone + Placebo
Iloperidone + Placebo is a phase 2 stage product being developed by Novartis for Post Traumatic Stress Disorder. The current trial status is terminated. This product is registered under clinical trial identifier NCT01917318. Target conditions include Post Traumatic Stress Disorder.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01917318 | Phase 2 | Terminated |
| NCT01464229 | Approved | Completed |
Competing Products
20 competing products in Post Traumatic Stress Disorder